Bibliography
- BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Phys. Rev. (1995) 75:725–748.
- ••A thorough review of the structure, function and nomencla-ture of the phosphodiesterase families.
- PRABHAKAR U, LIPSHUTZ D, O'LEARY BARTUS J et al.: Characterisation of c-AMP-dependent inhibition of LPS-induced TNF-a production by Rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Im-munopharmacol. (1994) 16:805–816.
- •First description of a selective PDE4 inhibitor.
- BOURNE HR, LICHTENSTEIN LM, MELMON KL et al.:Modulation of inflammation and immunity by cyclic AMP. Science (1974) 184:19–28.
- VERGHESE MW, MCCONNELL RT, STRICKLAND AB et al.:Differential regulation of human monocyte-derived TNF-a and IL-113 by Type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharm. Exp. Ther. (1995) 272:1313–1320.
- MARIVET MC, BOURGUIGNON JJ, LUGNIER C et al.: Inhi-bition of cyclic adenosine-3',5'-monophosphate phos-phodiesterase from vascular smooth muscle by Rolipram analogues. J. Med. Chem. (1989) 32:1450–1457.
- ••Review of structure-activity relationships of selective PDE4inhibitors.
- STAFFORD JA, FELDMAN PL: Chronic pulmonary in- flammation and other therapeutic applications of PDE IV inhibitors. In: Ann. Report Med. Chem. Academic Press (1996) Chapter 8, 71–81.
- •First investigation of non-dialkoxyphenyl ring analogues of rolipram.
- DAVIDSEN SK, SUMMERS JB: Inhibitors of TNF-a synthe-sis. Exp. Opin. Ther. Patents (1995) 5:1087–1100.
- PALFREYMAN MN: Phosphodiesterase Type IV inhibi-tors as antiinflammatory agents. Drugs Future (1995) 20:793–804.
- STAFFORD JA, FELDMAN PL, MARRON BE et al.:Structure-activity relationships involving the catechol subunit of Rolipram. Bioorg. Med. Chem. Letts. (1994) 4:1855–1860.
- DEBRITO FB, SOUNESS JE, WARNE PJ: Type 4 phos-phodiesterase inhibitors and their potential in the treatment of inflammatory disease. In: Emerging Drugs. Bowman WC, Fitzgerald JD, Taylor JB (Eds.) Ashley Publica-tions, London, UK (1997) 2:249–268.
- KARLSSON JA, ALDOUS D: Phosphodiesterase 4 inhibi-tors for the treatment of asthma. Exp. Opin. Ther. Patents (1997) 7:989–1003.
- BADGER AM, LEE JC: Advances in antiarthritic thera-peutics. Drug Disc. Today (1997) 2:427–435.
- MARRIOTT JB, WESTBY M, DALGLEISH AG: Therapeutic potential of TNF-a inhibitors old and new. Drug Disc. Today (1997) 2:273–82.
- BLACK RA, BIRD TA, MOHLER KM: Agents that blockTNF-a synthesis or activity. In: Ann. Report Med. Chem. Academic Press (1997) Chapter 24, 241–250.
- TORPHY TJ, STADEL JM, BURMAN M et al: Coexpressionof human cyclic AMP-specific phosphodiesterase ac-tivity and high-affinity Rolipram binding in yeast. J. Biol. Chem. (1992) 267:1798.
- BARNETTE MS, GROUS M, CIELSLINSKI LB: Inhibitors ofphosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol Exp. Ther. (1995) 273:1396–1402.